Skip to main content
77°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
RayzeBio, Inc. - Common Stock
(NQ:
RYZB
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about RayzeBio, Inc. - Common Stock
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
March 19, 2024
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer...
Via
Benzinga
The Best-Performing U.S. IPOs Of 2023
February 04, 2024
In 2023, there were 154 IPOs on the U.S. stock market. Here is a look at some of the best initial public offerings from last year.
Via
Talk Markets
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
Cramer Says This 'Inexpensive' Stock Is 'Doing Some Great Things With Aerospace'
January 05, 2024
Jim Cramer said WK Kellogg Co (NYSE: KLG) doesn’t have a "lot of growth, and it doesn’t have a lot of yield." He prefers Kellanova (NYSE: K)
Via
Benzinga
Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio
December 26, 2023
Via
Benzinga
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
December 29, 2023
The major indexes boast big annual gains with the Dow at record highs.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
December 29, 2023
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Via
Benzinga
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
December 27, 2023
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole...
Via
Benzinga
Investor Sentiment Improves; Dow Jumps Over 150 Points
December 27, 2023
The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the "Extreme Greed" zone on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher
December 26, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 26, 2023
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 26, 2023
Via
Benzinga
Stocks Extend Gains As Oil Prices Rise
December 26, 2023
The short sprint to the end of 2023 is off to a good start, with the Dow Jones Industrial Average, S&P 500 Index, and Nasdaq Composite all sporting solid gains this afternoon.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
December 26, 2023
Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower.
Via
Investor's Business Daily
Why Is RayzeBio (RYZB) Stock Up 100% Today?
December 26, 2023
RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024.
Via
InvestorPlace
Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals
December 26, 2023
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of <
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 26, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023
October 11, 2023
Via
Benzinga
RayzeBio Is A New Contender in Radiopharmaceutical Arena, Will Attract Prominent Entities: JP Morgan
October 10, 2023
JP Morgan has initiated coverage on RayzeBio Inc (NASDAQ: RYZB), representing a pure-play opportunity in the radiopharmaceutical space.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
October 10, 2023
Via
Benzinga
Specialty Asian Grocer Maison Solutions Opens For Trading
October 08, 2023
Following a couple of high-profile trading debuts, the IPO market slowed down again. There was only one public offering of note this week, with California-based specialty Asian grocer Maison Solutions...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
SoftBank-Owned Arm Jumps 20% In Market Debut
September 17, 2023
British chip designer Arm made its public debut on Thursday, with the shares jumping 10% right as the stock opened for trading. Arm's was the most high-profile Nasdaq IPO in the last few years, with...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
October 06, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
September 26, 2023
On Tuesday, 386 stocks made new 52-week lows.
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.